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ABSTRACT
Background. Magnesium (Mg2+) is an essential ion for cell
growth, neuroplasticity and muscle contraction. Blood Mg2+ le-
vels <0.7 mmol/Lmay cause a heterogeneous clinical phenotype,
including muscle cramps and epilepsy and disturbances in K+
and Ca2+ homeostasis. Over the last decade, the genetic origin
of several familial forms of hypomagnesaemia has been found.
In 2000, mutations in FXYD2, encoding the γ-subunit of the
Na+–K+-ATPase, were identiﬁed to cause isolated dominant
hypomagnesaemia (IDH) in a large Dutch family suffering
from hypomagnesaemia, hypocalciuria and chondrocalcinosis.
However, no additional patients have been identiﬁed since then.
Methods. Here, two families with hypomagnesaemia and
hypocalciuria were screened for mutations in the FXYD2
gene. Moreover, the patients were clinically and genetically
characterized.
Results.We report a p.Gly41Arg FXYD2mutation in two fam-
ilies with hypomagnesaemia and hypocalciuria. Interestingly,
this is the same mutation as was described in the original
study. As in the initial family, several patients suffered from
muscle cramps, chondrocalcinosis and epilepsy. Haplotype
analysis revealed an overlapping haplotype in all families, sug-
gesting a founder effect.
Conclusions. The recurrent p.Gly41Arg FXYD2 mutation in
two new families with IDH conﬁrms that FXYD2 mutation
causes hypomagnesaemia. Until now, no other FXYD2 muta-
tions have been reported which could indicate that other
FXYD2 mutations will not cause hypomagnesaemia or are
embryonically lethal.
Keywords: distal convoluted tubule, FXYD2, kidney,
magnesium, Na+–K+‐ATPase
INTRODUCTION
Hypomagnesaemia is a common electrolyte imbalance result-
ing in muscle cramps, muscle weakness and cardiac arrhyth-
mias [1]. The use of certain types of drugs including
calcineurin inhibitors, proton-pump inhibitors and diuretics
may cause low serum magnesium (Mg2+) levels [2]. In a
small percentage of patients, the Mg2+ disturbance is of genetic
origin [3]. Hypomagnesaemia-causing mutations often affect
Mg2+ transport processes operating in the renal distal convo-
luted tubule (DCT). The ﬁnal urinary Mg2+ excretion is deter-
mined in the DCT, since Mg2+ reabsorption does not take place
beyond that nephron segment [3]. As a consequence, patients
with reduced Mg2+ uptake in DCT have renal Mg2+ wasting.
In 2000, we identiﬁed a c.115G>A (p.Gly41Arg) mutation in
the FXYD domain containing ion transport regulator 2 gene
(FXYD2) causative for isolated dominant hypomagnesaemia
(IDH, [MIM 154020]) in a large Dutch family [4–6]. Although
originally described as two families, haplotype analysis revealed
a 10.5 cM overlapping region suggesting a founder effect [4].
Patients in this family had normal urinary Mg2+ values, but
showed lowered urinary Ca2+ excretion and suffered from
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episodes of convulsions [7]. Some patients developed symp-
toms of chondrocalcinosis, related to chronic hypomagnes-
aemia [8].
FXYD2 encodes the γ-subunit of the Na+–K+-ATPase and is
involved in stabilization of the α-subunit of that complex [9].
Moreover, the γ-subunit decreases the afﬁnity of the Na+–K+-
ATPase for Na+ and K+ and increases the afﬁnity for ATP
[10]. The p.Gly41Arg mutation causes a trafﬁcking defect pre-
venting the γ-subunit to reach the basolateral membrane [5,
11]. In the kidney, two splice variants of FXYD2 are expressed.
FXYD2a is expressed strongly in the thick ascending limb
and proximal tubule and only discretely in the DCT [12]. In
contrast, FXYD2b expression is restricted to the basolateral
membrane of the DCT and connecting tubule. In addition,
HNF-1-β can activate FXYD2a transcription, and mutations
in the HNF-1-β transcription factor gene (HNF1B) cause hypo-
magnesaemia [13–15]. Given that each FXYD2 splice variant
differentially modiﬁes Na+–K+-ATPase activity, it has been
hypothesized that the ratio between FXYD2a and FXYD2b ex-
pression may determine Na+–K+-ATPase activity. However,
the mechanism by which changes in basolateral FXYD2 ex-
pression affects renal Mg2+ reabsorption remains to be
elucidated.
Since the report of the original family in 2000, new families
with FXYD2mutations have not been described. As a result, the
relevance of FXYD2mutations for hypomagnesaemia has been
questioned over the years. For the ﬁrst time since the initial re-
port, we now present two new families harbouring the same p.
Glu41Arg mutation in FXYD2. To provide further insight into
the role of this mutation in hypomagnesaemia, full molecular
and genealogical analyses were performed. Furthermore, we
aimed to increase the current phenotypic knowledge and de-
scribe the clinical presentations and treatment of patients
with FXYD2 mutations.
MATERIALS AND METHODS
Patients
All patients in this study were diagnosed with hypomagnes-
aemia and were screened by the DNA diagnostics department
of the Radboudumc Nijmegen for hypomagnesaemia-causing
mutations. Informed consent for participation in research was
obtained in accordance with Institutional Review Board
guidelines. Serum and urine electrolytes were determined by gen-
eral laboratory screenings. Laboratory ﬁndings of all patients are
presented in Table 1.
Mutation analysis
Extraction of DNA from whole blood was performed using
standard protocols. FXYD2 mutation screening was performed
using polymerase chain reaction (PCR) primers designed on the
coding sequence of the human FXYD2 gene (NM_001680.4,
NM_021603.3) including exon–intron boundaries [5]. Ampliﬁed
sequences were separated on agarose gel by electrophoresis and dir-
ectly Sanger sequenced according to standard methods on a 3730
Sequence Analyzer (Applied Biosystems). Mutation nomenclature
is according toHGVSusingNM_001680.4 as a reference sequence.
Haplotype analysis
Microsatellite markers D11S4092, D11S4127, D11S939,
D11S1356 and D11S4195 encompassing the FXYD2 gene on
chromosome 11q23 were ampliﬁed by PCR using ﬂuorescently
labelled primers. PCR products are denatured and analysed on
a 3730 Sequence Analyzer (Applied Biosystems).
Genealogy study
In-depth genealogical analysis was performed to identify
common ancestors of FXYD2 patients. Lists of descendants
from index patients were compiled and pedigrees were gener-
ated using Dutch and Belgian civil registers and church books.
RESULTS
Recurrent FXYD2 mutation in patients
with hypomagnesaemia
In two families with hypomagnesaemia, a c.115G>A muta-
tion in the FXYD2 gene was identiﬁed by mutation analysis.
The mutation results in a p.Gly41Arg change at amino acid
level. Interestingly, the c.115G>A mutation has previously
been reported in a large Dutch family in 2000 and no other
FXYD2 mutations have been found since [5].
FXYD2 mutation in a Dutch family
The ﬁrst family is a Dutch family with three affected family
members (Figure 1). The proband (Figure 1, NL II.1) was dis-
covered suffering from hypokalaemia and hypomagnesaemia
during admission for lung embolism at the age of 34 (Table 1).
Table 1. Laboratory values of affected individuals
Patient NL II.1 NL III.1 NL III.2 B II.2 B III.2 B IV.1
Serum magnesium (mmol/L, nl 0.7–0.95) 0.38 0.45 0.45 0.56 0.35 0.5
Serum potassium (mmol/L, nl 3.5–5.1) 3.3 4.2 3.8 4.0 3.0 3.6
Serum bicarbonate (mmol/L, nl 21–27) 29.6 24 22 26 27 31
Serum sodium (mmol/L, nl 135–145) 138 142 142 137 139
eGFR (mL/1.73 mL/min, nl >90) 123 133 124 43 125 85
Urinary magnesium excretion/day (mmol/day, nl 3.0–5.0) 8.9 8.1 10.6 8.4
Fractional magnesium excretion (%, nl <4%) 8.3 11.9 6
Urinary calcium excretion/day (mmol/day, nl 1.5–7.5) 1.3 0.8 1.52 0.3
Urinary calc/creat (mmol/mmol, nl <0.7) 0.08 0.04 0.05
Urinary sodium excretion/day (mmol/day, nl 40–220) 119 358 218 147
1 meq Mg = 0.5 mmol Mg = 12.3 mg Mg. 1 meq Ca = 0.5 mmol Ca = 20.5 mg Ca (1 mmol = 41 mg) nl. = normal (reference value).
Note: Values in subject B II.2 are those recorded under supplementation, and not a presentation.
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He had a chronic history of muscle cramps and fatigue and re-
ported a spacious ﬂuid intake. He is an only child and his parents
are deceased.He reported no relevant symptoms of his father (Fig-
ure 1, NL I.1) besides a spacious ﬂuid intake and recurrentmiscar-
riages of his mother (Figure 1, NL I.2). The proband is currently
treated withMg2+ supplements stabilizing the serumMg2+ andK+
levels at ±0.45 and ±3.4 mmol/L, respectively.
Hereafter, his two children were admitted to the outpatient
clinic for evaluation because of muscle cramps. They both
showed hypomagnesaemia. The daughter (Figure 1, NL III.1),
9 years old, reported muscle cramps and uncertainty about
keeping balance, without falling. His son (Figure 1, NL III.2),
7 years old, reported an increased ﬂuid intake and nightly mus-
cle cramps and is known with an attention deﬁcit disorder. Both
children had a normal growth pattern, normal blood pressure, no
dysmorphic features and unremarkable renal ultrasound and X-
ray of the hand. Laboratory evaluation revealed isolated hypo-
magnesaemia with hypermagnesuria and hypocalciuria (with
normal serum creatinine) (Table 1). Because the dominant inher-
itance of hypomagnesaemia in this family was not compatible
with Gitelman syndrome, genetic analysis was performed for
diagnostic purposes. No mutations were found in the HNF1B
and SLC12A3 genes. A heterozygous missense mutation in the
FXYD2 gene [c.121G>A (p.Gly41Arg)] was found in all three af-
fected individuals. The children are free of symptoms with Mg2+
supplementation three times a day, achieving serumMg2+ and K+
concentrations in the low-normal range.
FXYD2 mutation in a Belgian family
The second family originates from Belgium. The proband is
a 67-year-oldman admitted for awork-up of hypokalaemia and
hypomagnesaemia (Figure 2, B II.2). Hypomagnesaemia and
hypokalaemia were ﬁrst discovered at age 44, during a blood
electrolyte analysis following an episode of tetanic cramps. Magne-
sium and potassium supplements were then initiated, with variable
compliance. The patient reported chronic fatigue, with general
weakness, dysesthesia of the face and hands, and frequent cramps
of the lower limbs, which generated difﬁculties inwalking.He com-
plained about continuous thirst and nocturia. Blood pressure was
180/85 mmHg (supine) and 150/90 mmHg (standing). The
clinical examination was otherwise unremarkable. The patient
had chondrocalcinosis evidenced by X-ray of the knees.
Bloodandurineanalyses revealedrenal failure (plasmacreatinine
1.62 mg/dL, eGFR 43 mL/min/m2), with hypomagnesaemia (all
serum electrolytes within normal range) hypermagnesuria and
hypocalciuria (Table 1). Facing the chronic history of hypomag-
nesaemiawith inappropriateurinaryMg2+lossandhypocalciuria,
Gitelman syndrome was suspected. Genetic testing of SLC12A3,
CLCNKB and HNF1B (sequencing of all exons, exon–intron
boundaries plus multiplex ligation-dependent probe ampliﬁca-
tion) was negative.
The patient reported that his mother (Figure 2, B I.2, de-
ceased at age 62) was known for Mg2+ problems. She suffered
from chronic fatigue and articulation problems. In addition, she
took Mg2+ supplements, as well as the probands daughter (B
III.2) and granddaughter (B IV.1).
The daughter of the proband (Figure 2, B III.2), aged
41 years, complained of fatigue since childhood, with limited
physical activity. She had cramps and dysesthesia of the face
and hands. She was diagnosed with hypomagnesaemia as a
young adult and has taken Mg2+ supplements since then. Plas-
ma analyses revealed persistent hypomagnesaemia and hypo-
kalaemia, with normal HCO3
− and normal renal function.
The urinary Mg2+ loss was inappropriately high (Table 1).
The granddaughter of the proband (B IV.1), aged 16 years,
experienced two epileptic crises at 5 and 15 years of age and
complained of chronic fatigue. The neurological work-up was
negative but hypomagnesaemia and hypokalaemia were no-
ticed, with inappropriate urinary Mg2+ loss and hypocalciuria
(Table 1). Renal function was normal.
Over the years, plasma Mg2+ remained, in the Belgian fam-
ily, below or just at the low-normal values despite supplemen-
tation. Follow-up K+ levels were improved, with levels of 4.5
mmol/L (B II.2), 3.75 mmol/L (B III.2) and 3.64 mmol/L (B
IV.1) observed 1 year after ﬁrst contact (Table 1). These values,
which were all within normal limits, were however variable and
not always conﬁrmed during follow-up in other institutions.
Common haplotype bearing the FXYD2 mutation
To examine whether the newly identiﬁed families share the
same haplotype as the original family, marker analysis was
F IGURE 1 : Family with isolated hypomagnesaemia from the Netherlands. (A) Pedigree of the Dutch family with hypomagnesaemia. Black-ﬁlled
symbols denote affected and genetically conﬁrmed family members, grey symbols denote potentially affected family members. (B) Mutation
analysis chromatogram of the proband (NL II.1). The mutation is indicated by an arrow and the nucleotide changes and resulting effect at the
amino acid level are shown.
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initiated. Five markers encompassing the FXYD2 gene were
selected: D11S4092, D11S4127, D11S939, D11S1356 and
D11S4195 (Figure 3). For this analysis, relatives from the ori-
ginal family were included. Indeed, patients from all three
families share the same haplotype, suggesting that the families
are related through a common ancestor. Genealogical analysis
did not result in the identiﬁcation of this common ancestor.
Although the Belgian family was shown to originate from
the same geographical region (surroundings of Liège, Bel-
gium) as the family described in the original paper from
2000, no common ancestor was found in 9–12 generations
back.
DISCUSSION
In this study, a c.115G>A (p.Gly41Arg) mutation in FXYD2
was identiﬁed in two families with hereditary hypomagnes-
aemia. Importantly, these are the ﬁrst new patients reported
since 2000 conﬁrming that FXYD2 mutations cause hypomag-
nesaemia. In both patient families, the same c.115G>A
mutation was detected that was previously described in a
large Dutch family. All three families shared the same haplo-
type, suggesting a founder effect.
Although the genetic cause was only found in 2000 [4],
the ﬁrst patients with mutations in the FXYD2 gene were clin-
ically evaluated in 1987 [16, 17]. Twenty-two individuals har-
bouring FXYD2 mutations showed IDH, hypocalciuria and
occasionally also hypomagnesaemia-associated chondrocalci-
nosis was detected. Since the ﬁrst identiﬁcation of the FXYD2
p.Gly41Arg mutation in 2000 [15], no other FXYD2mutations
have been reported in the literature or detected in our diagnos-
tic testing facility. Therefore, the role of FXYD2 in hypomagnes-
aemia has been questioned. The identiﬁcation of the newDutch
and Belgian families with FXYD2 mutations conﬁrms its im-
portance in renal Mg2+ handling. Moreover, several regulatory
factors of FXYD2 have additionally been implicated in Mg2+
homeostasis. The transcription of FXYD2 is induced by
HNF-1-β [14] and patients withHNF1Bmutations also develop
hypomagnesaemia (Renal Cyst and Diabetes syndrome, [MIM
137920]) [13]. Recently, pterin-4-α-carbinolamine dehydratase
(encoded by PCBD1) was identiﬁed as an additional
F IGURE 3 : Haplotype analysis of patients with FXYD2mutations. STSmarker analysis of patients with FXYD2mutations withmarkers from the
chromosome 11q23 (Chr11:117 250 000–118 000 000, hg38). All families share the same haplotype.
F IGURE 2 : Family with isolated hypomagnesaemia from Belgium. (A) Pedigree of the Belgian family with hypomagnesaemia. Blackened
symbols denote affected and genetically conﬁrmed family members, grey symbols denote potentially affected family members. (B) Mutation
analysis chromatogram of the proband (B II.2). The mutation is indicated by an arrow and the nucleotide changes and resulting effect at the amino
acid level are shown.
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transcriptional regulator of FXYD2 and again patients with
PCBD1 mutations showed hypomagnesaemia [MIM 126090]
[15]. Although the exact molecular mechanism by which the
PCBD1–HNF1B–FXYD2 axis regulates renal Mg2+ reabsorp-
tion is still unclear, the effects of FXYD2-encoded γ-subunit
on Na+–K+-ATPase activity have been well established. The
γ-subunit increases the afﬁnity of the Na+–K+-ATPase for
ATP and decreases the afﬁnity for Na+ and K+ [10]. The p.
Gly41 residue is located central in the α-helix that forms the
γ-subunit (PDB: 2mkv). Mutation of the small glycine residue
in the larger arginine residue may disrupt the structure of the γ-
subunit. To date, other FXYD2 mutations have not been identi-
ﬁed, suggesting that other FXYD2 mutations may not cause
hypomagnesaemia. Alternatively, the importance of γ-subunit
for Na+–K+-ATPase activity could suggest that more severe mu-
tations in FXYD2 render a dysfunctional Na+–K+-ATPase and
therefore may be embryonic lethal.
In the new families from the Netherlands and Belgium, both
hypomagnesaemia and hypocalciuria could be conﬁrmed in all
patients. Of note, hypomagnesaemia was associated with mod-
erate hypokalaemia in the two patients with lowest serumMg2+
values. Hypokalaemia is often secondary to hypomagnesaemia
[5]. Hypomagnesaemia results in decreased intracellular Mg2+
levels in the distal part of the nephron, possibly due to the fact
the Mg2+ normally inhibits the renal outer medullary K+ chan-
nel minimizing renal K+ secretion. In addition, several patients
reported high ﬂuid intake and thirst. These manifestations are
typically encountered in patients suffering from chronic hypo-
kalaemia, as described for instance in Gitelman syndrome [18,
19]. Hypokalaemia has been shown to induce a down-regula-
tion of AQP2 water channels in the collecting duct, impairing
the urinary concentration [20]. In turn, this could stimulate
compensatory thirst, in order to maintain the plasma osmolal-
ity and sodium levels.
Other clinical manifestations of the patients harbouring
FXYD2 mutations include renal failure (chronic kidney dis-
ease stage 3) (BE II.2), but other factors in the development
of renal failure cannot be excluded (e.g. analgesics and
NSAID for chronic pain due to chondrocalcinosis). All affected
family members reported muscle cramps. In addition, one pa-
tient suffered from episodes of epilepsy (B IV.1). Moreover,
chondrocalcinosis was detected in the proband of the Belgian
family (B II.2). Both epilepsy and chondrocalcinosis were ob-
served in the other patients from the original family [13, 14],
and are classical complications of hypomagnesaemia. In the
Dutch family, daily supplementation using Mg(OH)2 achieved
plasma Mg2+ levels in the low-normal range.
Genealogical analysis, going back to 1700 of all three pa-
tients’ families with the similar FXYD2mutation did not result
in the identiﬁcation of a common ancestor. Interestingly, the
ancestry of two families could be traced back to the same geo-
graphical area near Liège in Belgium. If indeed the common an-
cestor lived before 1700, the dominant inheritance of IDH
suggests that more, still unidentiﬁed, descendants of this com-
mon ancestor could live in the Netherlands and Belgium. How-
ever, given the variety of this phenotype and the non-
speciﬁcity of the symptoms these patients often remain un-
detected. Increasing the awareness of this syndrome may help
identifying more patients with FXYD2 mutations and allow
proper treatment by Mg2+ supplementation.
In conclusion, this study reports two new families with IDH
caused by FXYD2 mutations. Further insight in the clinical
spectrum associated with genetic Mg2+ disorders can provide
useful information for clinicians to make an early differential
diagnosis. FXYD2 mutations should be considered in patients
with hypomagnesaemia and hypocalciuria.
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ABSTRACT
Background. Dysfunction of mitochondria is involved in po-
docyte injury in some kidney diseases, but the relationship be-
tween abnormal mitochondrial morphology and podocyte
injury as well as the underlying mechanism is still unclear.
This study aims to investigate dynamic changes of mitochon-
drial morphology and the potential molecular events in an
adriamycin (ADR)-induced podocyte injury model.
Methods. Podocyte apoptosis was evaluated by annexin V
assay. Podocyte mitochondrial membrane potential (MMP)
was measured with MitoCapture kit. Double staining was
used to show the distribution changes of mitochondria and
actin ﬁlament as well as mitofusin proteins and podocin. Mito-
chondrial shape descriptors were obtained using analySIS
Image system. Effects of cyclosporine A (CsA) or minocycline
(Mcy) on mitochondrial morphology were explored in ADR-
induced nephropathy rats.
Results. ADR caused podocyte damage displaying as induction
of cellular apoptosis and increase of activated caspase 3 and
cytochrome c. The MMP level was decreased remarkably in
ADR-treated podocytes. Mitochondrial morphological changes
induced by ADR occurred rapidly from large and ellipsoid
shape to the small, long and irregular. ADR signiﬁcantly
decreased surface area, perimeter and circularity, while increas-
ing aspect ratio of mitochondria. In addition, mitochondria
number transiently increased at 6 h following ADR application.
Mitochondria intensity was increased along with punctate mito-
chondria formation, which co-localized with polymerized actin
cytoskeleton in ADR podocytes. In ADR-induced nephropathy
rats, 24-h proteinuria was decreased signiﬁcantly by CsA or
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